Literature DB >> 12750721

Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.

M B Thomas, C Koller, Y Yang, Y Shen, S O'Brien, H Kantarjian, J Davis, E Estey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750721     DOI: 10.1038/sj.leu.2402862

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.

Authors:  Apostolia Maria Tsimberidou; Michael J Keating; Elias J Jabbour; Farhad Ravandi-Kashani; Susan O'Brien; Elihu Estey; Neby Bekele; William K Plunkett; Hagop Kantarjian; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-03

2.  Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.

Authors:  Zhenyi Jin; Xiuli Wu; Shaohua Chen; Lijian Yang; Qifa Liu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2014-01-11       Impact factor: 3.311

3.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

4.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

5.  Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT.

Authors:  Li Xuan; Zhiping Fan; Yu Zhang; Hongsheng Zhou; Fen Huang; Min Dai; Danian Nie; Dongjun Lin; Na Xu; Xutao Guo; Qianli Jiang; Jing Sun; Yang Xiao; Qifa Liu
Journal:  Oncotarget       Date:  2016-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.